tumor was ER+ and/or PR+—tamoxifen. In the past decade, this approach was challenged by several findings. In 1998, a pivotal trial convincingly showed the clinical importance of tyrosine kinase signal transduction pathways by demonstrating that
Search Results
Ten Years of Progress Against Breast Cancer: A Partnership of Basic and Clinical/Translational Science
Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel
Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ
Michael J. Hassett, Wei Jiang, Melissa E. Hughes, Stephen Edge, Sara H. Javid, Joyce C. Niland, Richard Theriault, Yu-Ning Wong, Deborah Schrag, and Rinaa S. Punglia
had positive margins (3%); 31% were high grade. HR status was positive in 49%, but was missing in 42% of cases. Most women (83%) received RT for their initial DCIS; only 40% received AET. Of AET recipients, most (92%) took tamoxifen, 5% took an
PCL23-124: The Role of SMAD4/TGFβ Signaling in Tumorigenesis of Pancreatic Ductal Adenocarcinoma (PDAC)
Hannah Yoo and Anna Means
: IHC staining was performed on different precursor lesions of mouse pancreatic tissue (PanIN precursor: Ptf1aCre LSL-KrasG12D; IPMN precursor: Ptf1aCreERT LSL- KrasG12D Smad4fl/fltreated with tamoxifen) using markers of different IPMN subtypes and
Fertility Preservation in Patients With Breast Cancer: Necessity, Methods, and Safety
Adrienne G. Waks and Ann H. Partridge
cohorts. In women treated for hormone receptor–positive early-stage breast cancer, multiple studies demonstrate an association between tamoxifen use and persistence of postchemotherapy amenorrhea. 12 , 19 , 20 Rather than representing a gonadotoxic effect
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Bethany Anderson, Harold J. Burstein, Helen Chew, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice Lyons, Joanne Mortimer, Sameer A. Patel, Lori J. Pierce, Laura H. Rosenberger, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica S. Young, Jennifer Burns, and Rashmi Kumar
that took into account factors associated with lower IBTR, including grade, ER positive status, use of adjuvant tamoxifen, margin status, and age, the benefit of RT boost still remained statistically significant (HR, 0.69; 95% CI, 0.53–0.91; P <.010
Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression
Erin Currin, Lanell M. Peterson, Erin K. Schubert, Jeanne M. Link, Kenneth A. Krohn, Robert B. Livingston, David A. Mankoff, and Hannah M. Linden
lack of an accessible nonbone site of metastasis and patient refusal. She was treated with tamoxifen and bisphosphonate therapy with symptomatic improvement, with decline in tumor extent as measured by MRI and FDG-PET ( Figure 1, C ). Because of
Breast Cancer in Adolescents and Young Adults: A Review With a Focus on Biology
Jill R. Tichy, Elgene Lim, and Carey K. Anders
course. This section addresses endocrine therapy in adjuvant and metastatic settings, the controversy of ovarian suppression, and strategies with cytotoxic chemotherapy/targeted agents. Endocrine Therapy: Adjuvant Setting Adjuvant tamoxifen in
NCCN Task Force Report: Bone Health in Cancer Care
Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi N. Kumar, Charles L. Shapiro, Andrew Shields, Matthew R. Smith, Sandy Srinivas, and Catherine H. Van Poznak
postmenopausal osteoporotic women in a randomized trial of raloxifene . J Natl Cancer Inst 2004 ; 96 : 1751 – 1761 . 68 Vogel VG Costantino JP Wickerham DL . Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and
Modification and Implementation of NCCN Guidelines™ on Breast Cancer in the Middle East and North Africa Region
Omalkhair Abulkhair, Nagi Saghir, Lobna Sedky, Ahmed Saadedin, Heba Elzahwary, Neelam Siddiqui, Mervat Al Saleh, Fady Geara, Nuha Birido, Nadia Al-Eissa, Sana Al Sukhun, Huda Abdulkareem, Menar Mohamed Ayoub, Fawaz Deirawan, Salah Fayaz, Alaa Kandil, Sami Khatib, Mufid El-Mistiri, Dorria Salem, El Siah Hassan Sayd, Mohammed Jaloudi, Mohammad Jahanzeb, and William I. Gradishar
. Adjuvant Tamoxifen (Surveillance/Follow-up) Recommendations: Treatment with adjuvant tamoxifen during surveillance and follow-up should be considered a category 1 recommendation. Justification: In contrast to the findings reported by NSABP B-24, other
NCCN Guidelines Insights: Breast Cancer, Version 3.2018
Featured Updates to the NCCN Guidelines
Matthew P. Goetz, William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, William B. Farrar, Sharon H. Giordano, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Melinda L. Telli, John H. Ward, Jessica S. Young, Dorothy A. Shead, and Rashmi Kumar
evaluated breast cancer specimens from node-positive, HR-positive postmenopausal women (N=367) randomized to endocrine therapy with tamoxifen alone or chemotherapy with CAF (cyclophosphamide/doxorubicin/fluorouracil) followed by tamoxifen. 6 Compared with
